VEGFA and breast carcinoma: Baseline plasma VEGFA measured in advanced breast cancer patients before treatment with bevacizumab and vinorelbine showed that patients who had lower baseline plasma VEGFA had longer time to progress (9.3 months in patients with VEGFA ≤32.6 pg/mL vs. 3.7 months in patients with VEGFA >32.6 pg/mL) [48].